Laurent Peyrin-Biroulet to Young Adult
This is a "connection" page, showing publications Laurent Peyrin-Biroulet has written about Young Adult.
Connection Strength
0.137
-
Treatment Persistence for Infliximab Versus Adalimumab in Crohn's Disease: A 14-Year Single-Center Experience. Inflamm Bowel Dis. 2017 06; 23(6):976-985.
Score: 0.019
-
Value of cross-sectional imaging in assessing active Crohn's disease before stoma reversal. Dig Liver Dis. 2017 Aug; 49(8):864-871.
Score: 0.019
-
Azathioprine for refractory ulcerative proctitis: A retrospective multicenter study. Dig Liver Dis. 2017 Mar; 49(3):280-285.
Score: 0.019
-
Comparative Accuracy of Bowel Ultrasound Versus Magnetic Resonance Enterography in Combination With Colonoscopy in Assessing Crohn's Disease and Guiding Clinical Decision-making. J Crohns Colitis. 2018 Nov 15; 12(11):1280-1287.
Score: 0.005
-
Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study. Inflamm Bowel Dis. 2018 10 12; 24(11):2442-2451.
Score: 0.005
-
Efficacy and Safety of Induction Therapy With Calcineurin Inhibitors in Combination With Vedolizumab in Patients With Refractory Ulcerative Colitis. Clin Gastroenterol Hepatol. 2019 02; 17(3):494-501.
Score: 0.005
-
Anti-TNF therapy for genital fistulas in female patients with Crohn's disease: a nationwide study from the Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID). Aliment Pharmacol Ther. 2018 10; 48(8):831-838.
Score: 0.005
-
Clinical efficacy of the Toll-like receptor 9 agonist cobitolimod using patient-reported-outcomes defined clinical endpoints in patients with ulcerative colitis. Dig Liver Dis. 2018 10; 50(10):1019-1029.
Score: 0.005
-
Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn's Disease: A Systematic Review. Clin Gastroenterol Hepatol. 2018 09; 16(9):1407-1419.e22.
Score: 0.005
-
Independent Validation of a Self-Report Version of the IBD Disability Index (IBDDI) in a Population-Based Cohort of IBD Patients. Inflamm Bowel Dis. 2018 03 19; 24(4):766-774.
Score: 0.005
-
Effectiveness and safety of anti-TNF therapy for inflammatory bowel disease in liver transplant recipients for primary sclerosing cholangitis: A nationwide case series. Dig Liver Dis. 2018 07; 50(7):668-674.
Score: 0.005
-
Prolonged azathioprine treatment reduces the need for surgery in early Crohn's disease. J Gastroenterol Hepatol. 2018 Mar; 33(3):664-670.
Score: 0.005
-
Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease. Gastroenterology. 2018 04; 154(5):1343-1351.e1.
Score: 0.005
-
Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort. Aliment Pharmacol Ther. 2018 02; 47(4):485-493.
Score: 0.005
-
High Risk of Anal and Rectal Cancer in Patients With Anal and/or Perianal Crohn's Disease. Clin Gastroenterol Hepatol. 2018 06; 16(6):892-899.e2.
Score: 0.005
-
Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis. Aliment Pharmacol Ther. 2018 01; 47(2):219-228.
Score: 0.005
-
Distinct Thresholds of Infliximab Trough Level Are Associated with Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease: A Prospective Observational Study. Inflamm Bowel Dis. 2017 11; 23(11):2048-2053.
Score: 0.005
-
Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial. Aliment Pharmacol Ther. 2017 07; 46(2):142-149.
Score: 0.005
-
Validation of the Inflammatory Bowel Disease Disability Index in a population-based cohort. Gut. 2017 04; 66(4):588-596.
Score: 0.004